Italia markets close in 1 hour 9 minutes

FTSE MIB
33.564,51
-142,70(-0,42%)
Dow Jones
38.961,45
-150,71(-0,39%)
Nasdaq
17.767,63
+49,98(+0,28%)
Nikkei 225
39.667,07
+493,92(+1,26%)
Petrolio
81,03
+0,20(+0,25%)
Bitcoin EUR
57.932,99
+449,42(+0,78%)

NBIX Jul 2024 140.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

2,2900

-0,0100

(-0,43%)

In data: 03:06PM EDT. Mercato aperto.

Caricamento grafico interattivo in corso...

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat